search.noResults

search.searching

note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
NEWSWIRE


WHO updates Essential Medicines list with new advice on use of antibiotics


New advice on which antibiotics to use for common infections and which to pre- serve for the most serious circumstances is among the additions to the WHO Model list of essential medicines for 2017. Other additions include medicines for HIV, hepa- titis C, tuberculosis and leukemia. The updated list adds 30 medicines for


adults and 25 for children, and specifi es new uses for 9 already-listed products,


bringing the total to 433 drugs deemed es- sential for addressing the most important public health needs. The WHO Essential Medicines List (EML) is used by many countries to increase access to medicines and guide decisions about which prod- ucts they ensure are available for their populations.


New advice: 3 categories of antibiotic In the biggest revision of the antibiot- ics section in the EML’s 40-year history, WHO experts have grouped antibiotics


into three categories – ACCESS, WATCH and RESERVE – with recommendations on when each category should be used. Initially, the new categories apply only to antibiotics used to treat 21 of the most common general infections. If shown to be useful, it could be broadened in future versions of the EML to apply to drugs to treat other infections.


The change aims to ensure that antibiot-


ics are available when needed, and that the right antibiotics are prescribed for the right infections. It should enhance treat- ment outcomes, reduce the development of drug-resistant bacteria, and preserve the effectiveness of “last resort” antibiotics that are needed when all others fail. These changes support WHO’s Global action plan on antimicrobial resistance, which aims to fi ght the development of drug resistance by ensuring the best use of antibiotics. WHO recommends that antibiotics in the ACCESS group be available at all times as treatments for a wide range of common infections. For example, it includes amoxi- cillin, a widely-used antibiotic to treat infections such as pneumonia. The WATCH group includes antibiotics


that are recommended as fi rst- or second- choice treatments for a small number of infections. For example, the use of cipro- fl oxacin, used to treat cystitis (a type of urinary tract infection) and upper respi- ratory tract infections (such as bacterial sinusitis and bacterial bronchitis), should be dramatically reduced to avoid further development of resistance. The third group, RESERVE, includes


antibiotics such as colistin and some cephalosporins that should be considered last-resort options, and used only in the most severe circumstances when all other alternatives have failed, such as for life- threatening infections due to multidrug- resistant bacteria.


FDA approves fi rst cancer treatment for any solid tumor with a specifi c genetic feature The U.S. Food and Drug Administration granted accelerated approval to a treatment for patients whose cancers have a specifi c genetic feature (biomarker). This is the fi rst time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.


Keytruda (pembrolizumab) is indicated for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors that have been identifi ed as having a biomarker referred to as microsat- ellite instability-high (MSI-H) or mismatch repair defi cient (dMMR). HPN


Visit www.ksrleads.com/?707hp-004 8 July 2017 • HEALTHCARE PURCHASING NEWS • hpnonline.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58